Navigation Links
Lexicon To Present At The Needham Healthcare Conference
Date:4/25/2013

THE WOODLANDS, Texas, April 25, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Arthur Sands , M.D., Ph.D., president and  chief executive officer, will present at the Needham Healthcare Conference on Tuesday, April 30, at 2:20 PM EST in New York City. Dr. Sands will provide an overview of Lexicon's clinical development programs and milestones.

A webcast of the presentation will be available through Lexicon's website at www.lexpharma.com. An archived version of the presentation will be available at www.lexpharma.com until May 30, 2013.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has multiple programs in clinical development for diabetes, irritable bowel syndrome, carcinoid syndrome and other indications, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2012, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

 

 

 


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results
2. Lexicon To Present At The BIO CEO & Investor Conference
3. Lexicon Pharmaceuticals To Present At The Piper Jaffray Annual Healthcare Conference
4. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2012 Third Quarter Results
5. Lexicon to Provide Third Quarter 2012 Financial Results
6. Lexicon Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference
7. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
8. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
9. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
10. Lexicon to Provide Second Quarter 2012 Financial Results
11. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... 2017  The global market for liquid biopsy diagnostic ... million in 2016.  Although in early stages, the global ... particular as a result of the gradual shift towards ... introduction of a significant number of new liquid biopsy ... tumor biomarkers to guide treatment decisions. ...
(Date:7/10/2017)... 2017  US medical equipment and supply demand is ... Medical Equipment & Supplies: United States ... Continued increases in demand for medical services – driven ... and supported by gains in disposable personal income – ... product introductions will also drive sales as providers and ...
(Date:7/10/2017)... TRIANGLE PARK, N.C. , July 10, 2017 /PRNewswire/ ... a $5m Convertible Note to support the development of ... by Tencent Holdings Limited, a leading Chinese Internet services ... This funding will advance multiple infectious disease product programs ... Founded by Dr. ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... 24, 2017 , ... SignatureCare Emergency Center is looking to award ... semester to a deserving student. Get your applications in now as the deadline ... Mariana Castillo who is a nursing student at Prairie View A&M University with a ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... scholarship awards to be awarded annually to and divided between two full-time university ... bringing awareness to Amazonian plant medicine. To apply for the scholarship, students are ...
(Date:7/24/2017)... ... July 24, 2017 , ... Independence ... work hand-in-hand on an Innovation Collaboration program, have signed a five-year agreement that ... cost of the care members and patients receive. The agreement also signifies Jefferson ...
(Date:7/24/2017)... ... July 24, 2017 , ... Sharon Kleyne, host of the nationally syndicated ... VoiceAmerica sponsored by Nature’s Tears® EyeMist® recently talked on the air about an alarming ... , The article by Zidor Aldama described the situation in which Chinese children are ...
(Date:7/24/2017)... PA (PRWEB) , ... July 24, 2017 , ... ... 2030, today CURE announced that they have enrolled over 100,000 children in their ... afflicted children born every year in areas where treatment is limited or non-existent. ...
Breaking Medicine News(10 mins):